UY28513A1 - Nuevos compuestos - Google Patents

Nuevos compuestos

Info

Publication number
UY28513A1
UY28513A1 UY28513A UY28513A UY28513A1 UY 28513 A1 UY28513 A1 UY 28513A1 UY 28513 A UY28513 A UY 28513A UY 28513 A UY28513 A UY 28513A UY 28513 A1 UY28513 A1 UY 28513A1
Authority
UY
Uruguay
Prior art keywords
new compounds
compounds
racemates
tautomers
therapy
Prior art date
Application number
UY28513A
Other languages
English (en)
Spanish (es)
Inventor
Hansen Peter
Lonn Hans
Lawitz Karolina
Nikitidis Antonios
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29212489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28513(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY28513A1 publication Critical patent/UY28513A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • C07D213/85Nitriles in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
UY28513A 2003-09-18 2004-09-15 Nuevos compuestos UY28513A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0302487A SE0302487D0 (sv) 2003-09-18 2003-09-18 Novel compounds

Publications (1)

Publication Number Publication Date
UY28513A1 true UY28513A1 (es) 2005-04-29

Family

ID=29212489

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28513A UY28513A1 (es) 2003-09-18 2004-09-15 Nuevos compuestos

Country Status (25)

Country Link
US (1) US20070043036A1 (enExample)
EP (1) EP1663974B1 (enExample)
JP (1) JP2007505902A (enExample)
KR (1) KR20060096995A (enExample)
CN (1) CN100439339C (enExample)
AR (1) AR046083A1 (enExample)
AT (1) ATE420861T1 (enExample)
AU (1) AU2004272485B2 (enExample)
BR (1) BRPI0414570A (enExample)
CA (1) CA2538410A1 (enExample)
CO (1) CO5670357A2 (enExample)
DE (1) DE602004019110D1 (enExample)
ES (1) ES2319300T3 (enExample)
IL (1) IL173986A0 (enExample)
IS (1) IS8394A (enExample)
MX (1) MXPA06002723A (enExample)
NO (1) NO20061700L (enExample)
RU (1) RU2348617C2 (enExample)
SA (1) SA04250300B1 (enExample)
SE (1) SE0302487D0 (enExample)
TW (1) TW200526579A (enExample)
UA (1) UA84878C2 (enExample)
UY (1) UY28513A1 (enExample)
WO (1) WO2005026124A1 (enExample)
ZA (1) ZA200602262B (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200700392A (en) * 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
RS53599B1 (sr) 2005-05-10 2015-02-27 Intermune, Inc. Piridon derivati za modulaciju stresom aktiviranog sistema proteinskih kinaza
RU2442771C2 (ru) 2005-08-08 2012-02-20 Арджента Дискавери Лтд Производные бицикло[2,2,1]гепт-7-иламина и их применения
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
US20070104699A1 (en) * 2005-09-29 2007-05-10 University Of Alberta Compositions for and methods of granzyme B inhibition
GB0605469D0 (en) * 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
US8470859B2 (en) 2006-10-23 2013-06-25 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
CN101535264B (zh) 2006-11-08 2012-11-28 百时美施贵宝公司 吡啶酮化合物
MX2010004673A (es) 2007-11-06 2010-05-27 Astrazeneca Ab Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos.
CA2707785C (en) 2007-12-14 2015-11-03 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
WO2009094417A1 (en) 2008-01-23 2009-07-30 Bristol-Myers Squibb Company 4-pyridinone compounds and their use for cancer
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン, インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
CN102395586A (zh) 2009-02-17 2012-03-28 奇斯药制品公司 作为p38map激酶抑制剂的三唑并吡啶衍生物
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
CN102639505A (zh) * 2009-10-02 2012-08-15 阿斯利康(瑞典)有限公司 用作嗜中性白细胞弹性蛋白酶抑制剂的吡啶-2-酮化合物
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
MX2012006524A (es) * 2009-12-08 2012-07-17 Boehringer Ingelheim Int Proceso para la sintesis de compuestos intermedios de utilidad para preparar compuestos sustituidos de indazol y azaindol.
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
US9040516B2 (en) 2011-08-01 2015-05-26 Sumitomo Dainippon Pharma Co., Ltd. Uracil derivative and use thereof for medical purposes
PE20141370A1 (es) 2011-12-09 2014-10-17 Chiesi Farma Spa Inhibidores de quinasa
BR112014013177A2 (pt) 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
CA2858420A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
AR096532A1 (es) 2013-06-06 2016-01-13 Chiesi Farm Spa Inhibidores de quinasa
US9221807B2 (en) * 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
HK1249504A1 (zh) 2015-09-02 2018-11-02 Glaxosmithkline Intellectual Property (No. 2) Limited 用作溴结构域抑制剂的吡啶酮二甲酰胺
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
AR107164A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa INHIBIDORES DE QUINASA p38
AR107163A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
EP3394059B1 (en) 2015-12-23 2020-11-25 Chiesi Farmaceutici S.p.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
WO2017191098A1 (en) 2016-05-05 2017-11-09 F. Hoffmann-La Roche Ag Pyrazole derivatives, compositions and therapeutic use thereof
JP7050761B2 (ja) 2016-09-06 2022-04-08 エフ.ホフマン-ラ ロシュ アーゲー 8-(アゼチジン-1-イル)-[1,2,4]トリアゾロ[1,5-a]ピリジニル化合物、組成物及びその使用方法
CR20190310A (es) 2016-12-29 2019-08-21 Hoffmann La Roche Compuestos de pirazolopirimidina y métodos de uso de los mismos
JP2020510061A (ja) 2017-03-14 2020-04-02 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ピラゾロクロロフェニル化合物、組成物及びその使用方法
EP3630767A1 (en) 2017-05-22 2020-04-08 H. Hoffnabb-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
RU2769696C2 (ru) 2017-05-22 2022-04-05 Ф. Хоффманн-Ля Рош Аг Терапевтические соединения и композиции и способы их применения
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
EP3740488A1 (en) 2018-01-15 2020-11-25 F. Hoffmann-La Roche AG Pyrazolopyrimidine compounds as jak inhibitors
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂
CN110192948B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿腹部热敷贴
CN110192947B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿肺部热敷贴
CN114008050B (zh) 2019-06-18 2024-12-31 豪夫迈·罗氏有限公司 Jak激酶的吡唑并嘧啶芳基醚抑制剂及其用途
TW202115069A (zh) 2019-06-18 2021-04-16 瑞士商赫孚孟拉羅股份公司 Jak激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途
PE20220577A1 (es) 2019-06-18 2022-04-20 Hoffmann La Roche Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos
BR112022004861A2 (pt) 2019-09-17 2022-06-07 Univ Duke Alvelestat para uso no tratamento de rejeição de transplante, síndrome de bronquiolite obliterante e doença de transplante versus hospedeiro
SI4106757T1 (sl) 2020-04-16 2023-11-30 Mereo Biopharma 4 Limited Postopki, ki vključujejo zaviralec nevtrofilne elastaze alvelestat, za zdravljenje bolezni dihal, ki jo sproži pomanjkanje antitripsina alfa-1
IL312002A (en) 2021-10-20 2024-06-01 Mereo Biopharma 4 Ltd Neutrophil elastase inhibitors for use in the treatment of fibrosis
CN114057630B (zh) * 2021-12-23 2023-06-02 郑州大学 吡非尼酮衍生物及其合成方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
GB9207145D0 (en) * 1991-04-18 1992-05-13 Ici Plc Heterocyclic amides
FR2687674B1 (fr) * 1992-02-07 1995-05-19 Roussel Uclaf Nouveaux derives de la pyridone, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
CA2176043A1 (en) * 1993-11-19 1995-05-26 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
RU2067579C1 (ru) * 1994-10-07 1996-10-10 Пермский фармацевтический институт 3-(2'-нафтоилметилен)-пиперазинон-2 и 1-n-фенил-3-фенацилиденпиперазинон-2, проявляющие противовоспалительную активность
DE60139506D1 (de) * 2000-12-28 2009-09-17 Shionogi & Co 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
GB2383326A (en) * 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines
JP4486817B2 (ja) * 2001-12-20 2010-06-23 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 1,4−ジヒドロ−1,4−ジフェニルピリジン誘導体
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
HK1089167A1 (en) 2006-11-24
IL173986A0 (en) 2006-07-05
KR20060096995A (ko) 2006-09-13
EP1663974B1 (en) 2009-01-14
SE0302487D0 (sv) 2003-09-18
AU2004272485B2 (en) 2008-03-13
UA84878C2 (ru) 2008-12-10
RU2348617C2 (ru) 2009-03-10
JP2007505902A (ja) 2007-03-15
IS8394A (is) 2006-03-31
BRPI0414570A (pt) 2006-11-07
AU2004272485A1 (en) 2005-03-24
NO20061700L (no) 2006-04-18
CN100439339C (zh) 2008-12-03
CA2538410A1 (en) 2005-03-24
WO2005026124A1 (en) 2005-03-24
CO5670357A2 (es) 2006-08-31
MXPA06002723A (es) 2006-06-06
US20070043036A1 (en) 2007-02-22
EP1663974A1 (en) 2006-06-07
SA04250300B1 (ar) 2008-09-07
ZA200602262B (en) 2007-07-25
TW200526579A (en) 2005-08-16
DE602004019110D1 (de) 2009-03-05
ATE420861T1 (de) 2009-01-15
ES2319300T3 (es) 2009-05-06
AR046083A1 (es) 2005-11-23
RU2006112427A (ru) 2007-11-10
CN1856467A (zh) 2006-11-01

Similar Documents

Publication Publication Date Title
UY28513A1 (es) Nuevos compuestos
UY28514A1 (es) Nuevos compuestos
UY28946A1 (es) Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios
CR11517A (es) Derivados bis-(sulfonilamino) para uso en terapia
UY28572A1 (es) Compuestos novedosos
UY30327A1 (es) Nuevos compuestos ii
SE0302324D0 (sv) Novel compounds
ECSP045255A (es) Cumarinas utiles como biomarcadores
TW200500341A (en) Novel compounds
ECSP099044A (es) Compuestos de pirimido fusionados
UY28342A1 (es) Nuevos compuestos
SE0302323D0 (sv) Novel compounds
CR8986A (es) Isoxazoles sustituidos como fungicidas
PA8557401A1 (es) Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
ECSP066467A (es) Formas Polimórficas de 3-(4-amino-1-Oxo-1-3 DIhidroisoindol-2-IL)-Piperidin-2,6-Diona
ECSP10010178A (es) Derivados bis-(sulfonilamino) en terapia 066
ECSP077259A (es) Derivados de pirimidina
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
DOP2002000433A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso
UY29420A1 (es) Derivados de 2-piridona,composiciones que los contienen, procesos de preparación y aplicación
CR8559A (es) Pirazolopirimidinas
PA8577201A1 (es) 3-fenil-propionamido, 3-fenil-acrilamido y derivados 3-fenil-propinamido como inhibidores de mao-b
UY28694A1 (es) Nuevos compuestos
ECSP045219A (es) Derivados de quinazolinona y su uso como agonistas cb

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120322